Naltrexone-induced nausea in patients treated for alcohol dependence: Clinical predictors and evidence for opioid-mediated effects

Journal of Clinical Psychopharmacology

Volumn 20, Issue 1, 2000, Pages 69-76

  O'Malley, Stephanie S ^a   Krishnan Sarin, Suchitra ^a   Farren, Conor ^a   O'Connor, Patrick G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE; OPIATE RECEPTOR;

ADULT; AGE; AGED; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RISK FACTOR; SCORING SYSTEM; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALCOHOLISM; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; NAUSEA; SEX FACTORS; TEMPERANCE;

EID: 0033972388     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200002000-00012     Document Type: Article

References (37)

1. O'Malley SS, Jaffe A, Chang GM, Schottenfeld RS, Meyer RE, Rounsaville BJ. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992; 49:881-7.
2. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876-80.
3. Pohorecky LA, Brick J. Pharmacology of ethanol. Pharmacol Ther 1988;36:335-427.
4. Judson BA, Himmelberger DU, Goldstein A. The naloxone test for opiate dependence. Clin Pharmacol Ther 1980;27:492-501.
5. Croop RS, Faulkner EB, Labriola DF for the Naltrexone Usage Study Group. The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. Arch Gen Psychiatry 1997;54:1130-5.
6. Charney DS, Redmond DE, Galloway MP, Kleber HD, Heninger GR, Murberg M, Roth RH. Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: evidence for noradrenergic hyperactivity. Life Sci 1984;35:1263-72.
7. Kleber HD, Kosten TR. Naltrexone induction: psychologic and pharmacological strategies. J Clin Psychiatry 1984;45:29-38.
8. Froehlich JC. Interactions between alcohol and the endogenous opioid system. In: Zakhari S, ed. Alcohol and the endocrine system. Monograph 23, NIAAA Research Monograph Series. Washington, DC: U.S. Government Printing Office, 1993:21-35.
9. Wilkins JN, Gorelick DA. Clinical neuroendocrinology and neuropharmacology of alcohol withdrawal. In: Galanter M, ed. Recent developments in alcoholism, vol 4. New York: Plenum Press, 1986:241-63.
10. O'Connor PG, Farren CK, Rounsaville BJ, O'Malley SS. A preliminary investigation of the management of alcohol dependence with naltrexone by primary care providers. Am J Med 1997;103:477-82.
11. Kadden R, Carroll K, Donovan D, Cooney N, Monti P, Abrams D, Litt M, Hester R, eds. Cognitive behavioral coping skills therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence. Monograph 23, NIAAA Research Monograph Series. Washington, DC: U.S. Government Printing Office, 1992.
12. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported ethanol consumption. In: Allen J, Litten R, eds. Measuring alcohol consumption: psychological and biochemical methods. Totowa, NJ: Humana Press, 1992:42-72.
13. Spivey JR, Jorgensen RA, Gores GJ, Lindor KD. Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 1994;89:2028-32.
14. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1989.
15. Kleinbaum DG. Logistic regression: a self-learning text. New York: Springer-Verlag, 1994.
16. Menard S. Logistic regression analysis. Thousand Oaks, CA: Sage Publications, 1995.
17. Gambert SR, Garthwaite TL, Pontzer CH, Hagen TC. Age-related changes in central nervous system beta-endorphin and ACTH. Neuroendocrinology 1980;31:252-5.
18. Macintyre PE, Jarvis DA. Age is the best predictor of postoperative morphine requirements. Pain 1996;64:357-64.
19. Piva F, Limonta P, Dondi D, Pimpinelli F, Martini L, Maggi R. Effects of steroids on the brain opioid system. J Steroid Biochem Mol Biol 1994;53:343-8.
20. 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs 1998; 55:173-89.
21. Gianoulakis C. Endogenous opioids and excessive alcohol consumption. J Psychiatry Neurosci 1993;18:148-56.
22. McGrath PJ, Nunes EV, Qutkin FM. Naltrexone treatment of aclively drinking alcoholics [abstract]. Alcohol Clin Exp Res 1996; 20:44A.
23. Markley HG, Mezey E. Induction of alcohol withdrawal symptoms by nalorphine in chronic alcoholic patients. Int J Addict 1978;13: 395-402.
24. Seizinger BR, Hollt V, Herz A. Effect of chronic ethanol treatment on the in vitro biosynthesis of pro-opiomelanocortin and its post-translational processing to B-endorphin in the intermediate lobe of the rat pituitary. J Neurochem 1984;43:607-13.
25. Dave JR, Eiden LE, Karanian JW, Eskay RL. Ethanol exposure decreases pituitary corticotropin-releasing factor binding, adenylate cyclase activity, proopiomelanocortin biosynthesis and plasma B-endorphin levels in the rat. Endocrinology 1986;118:280-6.
26. Gianaloukis C. Long term ethanol alters the binding of 3H-opiates to brain membranes. Life Sci 1983;33:725-33.
27. Charness ME. Ethanol and opioid receptor signaling. Experentia 1989;45:518-28.
28. Hoffman PL, Chung CT, Tabakoff B. Effects of ethanol, temperature, and endogenous regulatory factors on the characteristics of striatal opiate receptors. J Neurochem 1984;43:1003-10.
29. Tabakoff B, Urwyler S, Hoffman PL. Ethanol alters kinetic characteristics and function of striatal morphine receptors. J Neurochem 1981;37:518-21.
30. Boyadjieva NI, Sarkar DK. Effects of chronic alcohol on immunoreactive beta-endorphin secretion from hypothalamic neurons in primary cultures: evidence for alcohol tolerance, withdrawal, and sensitization responses. Alcohol Clin Exp Res 1994; 18:1497-501.
31. Borg S, Kvande H, Rydberg U, Terenius L, Wahlstrom A. Endorphin levels in human cerebrospinal fluid during alcohol intoxication and withdrawal. Psychopharmacology (Berl) 1982;78:101-3.
32. Hoensch H. Ethanol as enzyme inducer and inhibitor. Pharmacol Ther 1987;33:121-8.
33. Crabtree BL. Review of naltrexone, a long-acting opiate antagonist. Clin Pharm 1984;273-280.
34. King AC, Volpicelli JR, Gunduz M, O'Brien CP, Kreek MJ. Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res 1997;21: 906-9.
35. O'Malley SS, Krishnan-Sarin S, Farren CK, Sinha R. Nicotine pretreatment attenuates naltrexone induced side effects in alcoholic smokers [abstract]. Alcohol Clin Exp Res 1996;20:109A.
36. Anton RF, Becker HC. Pharmacotherapy and pathophysiology. In: Kranzler HR, ed. Handbook of experimental pharmacology, vol 114: the pharmacology of alcohol abuse. New York: Spinger-Verlag, 1995:315-67.
37. Kleber HD, Riordan CE, Rounsaville BJ, Kosten T, Charney D, Gaspari J, Hogan I, O'Connor PG. Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry 1985; 42:391-4.